Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Adjunct Balloon Dilation after Long Everolimus-eluting Stent Deployment on Major Adverse Cardiac Events

  • Hong, Sung-Jin (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Ahn, Chul-Min (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Shin, Dong-Ho (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Kim, Jung-Sun (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Kim, Byeong-Keuk (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Ko, Young-Guk (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Choi, Donghoon (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Her, Ae-Young (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Kim, Yong Hoon (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Jang, Yangsoo (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System) ;
  • Hong, Myeong-Ki (Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System)
  • Received : 2017.01.23
  • Accepted : 2017.04.28
  • Published : 2017.09.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: The effectiveness of adjunct balloon dilation after drug-eluting stent (DES) deployment has not been sufficiently evaluated. We evaluated whether adjunct balloon dilation was associated with a reduction in major adverse cardiac events (MACEs) after long everolimus-eluting stents (EESs) implantation. Subjects and Methods: Drawing from 2 randomized trials, a total of 1,672 patients treated with long EES were analyzed. Of 1,672 patients, 1,061 patients (64%) received post-stent adjunct balloon dilation. MACE, defined as a composite of cardiac death, myocardial infarction, and target-lesion revascularization (TLR), was compared between patients who received post-stent adjunct balloon dilation and patients who did not in 595 propensity score-matched pairs. Results: For the matched population, MACE occurred in 29 patients (4.9%) who received adjunct balloon dilation and in 29 patients (4.9%) who did not (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.60-1.69; p=0.972). However, significant interactions were observed among the subgroups for clinical presentation and vessel size. Adjunct balloon dilation was more favored within the subset of patients with stable angina vs. the subset of patients with acute coronary syndrome (p for interaction=0.037), and within the subset of lesions with small vessel diameter (reference vessel diameter [RVD] <3 mm) vs. the subset of lesions with larger vessel diameter (RVD ${\geq}3mm$; p for interaction=0.027). Conclusion: Adjunct balloon dilation was not associated with MACE reduction at 1 year among patients requiring long EES implantation. However, post-stent adjunct balloon dilation may be necessary for patients requiring long EES implantation who present with stable angina or for lesions with small vessel diameters.

Keywords

Acknowledgement

Supported by : Ministry of Health and Welfare, National Research Foundation of Korea (NRF), Cardiovascular Research Center

References

  1. Brodie BR, Cooper C, Jones M, Fitzgerald P, Cummins FPostdilatation Clinical Compartative Study (POSTIT) Investigators. Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT trial. Catheter Cardiovasc Interv 2003;59:184-92. https://doi.org/10.1002/ccd.10474
  2. Russo RJ, Silva PD, Teirstein PS, et al. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial). Circ Cardiovasc Interv 2009;2:113-23. https://doi.org/10.1161/CIRCINTERVENTIONS.108.778647
  3. Hur SH, Kitamura K, Morino Y, et al. Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound. Am J Cardiol 2001;88:1114-9. https://doi.org/10.1016/S0002-9149(01)02044-6
  4. Romagnoli E, Sangiorgi GM, Cosgrave J, Guillet E, Colombo A. Drug-eluting stenting: the case for post-dilation. JACC Cardiovasc Interv 2008;1:22-31. https://doi.org/10.1016/j.jcin.2007.10.005
  5. Hoffmann R, Guagliumi G, Musumeci G, et al. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials. Catheter Cardiovasc Interv 2005;66:499-506. https://doi.org/10.1002/ccd.20542
  6. Iakovou I, Mintz GS, Dangas G, et al. Increased CK-MB release is a “trade-off” for optimal stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 2003;42:1900-5. https://doi.org/10.1016/j.jacc.2003.06.012
  7. Pasceri V, Pelliccia F, Pristipino C, et al. Clinical effects of routine postdilatation of drug-eluting stents. Catheter Cardiovasc Interv 2014;83:898-904. https://doi.org/10.1002/ccd.24999
  8. Frobert O, Sarno G, James SK, Saleh N, Lagerqvist B. Effect of stent inflation pressure and post-dilatation on the outcome of coronary artery intervention. A report of more than 90,000 stent implantations. PLoS One 2013;8:e56348. https://doi.org/10.1371/journal.pone.0056348
  9. Hong SJ, Kim BK, Shin DH, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA 2015;314:2155-63. https://doi.org/10.1001/jama.2015.15454
  10. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340-8. https://doi.org/10.1016/j.jacc.2012.06.043
  11. Kim JS, Kang TS, Mintz GS, et al. Randomized comparison of clinical outcomes between intravascular ultrasound and angiography-guided drug-eluting stent implantation for long coronary artery stenoses. JACC Cardiovasc Interv 2013;6:369-76. https://doi.org/10.1016/j.jcin.2012.11.009
  12. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8. https://doi.org/10.1161/01.CIR.100.18.1872
  13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51. https://doi.org/10.1161/CIRCULATIONAHA.106.685313
  14. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012;126:2020-35. https://doi.org/10.1161/CIR.0b013e31826e1058
  15. Steg PG, Serruys PW, Abdelghani M, Wijns W. The year in cardiology 2015: coronary intervention. Eur Heart J 2016;37:335-43.
  16. Srour JF, Abbott JD. Routine postdilation of drug-eluting stents: worth the gain. Catheter Cardiovasc Interv 2014;83:905-6. https://doi.org/10.1002/ccd.25481
  17. Dangas GD, Serruys PW, Kereiakes DJ, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013;6:914-22. https://doi.org/10.1016/j.jcin.2013.05.005
  18. Kim JS, Kim JH, Shin DH, et al. Serial randomized comparison of strut coverage of everolimus- and first-generation sirolimus-eluting stents. Can J Cardiol 2015;31:723-30. https://doi.org/10.1016/j.cjca.2015.01.002
  19. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402. https://doi.org/10.1016/S0140-6736(12)60324-9
  20. Zhang ZJ, Marroquin OC, Stone RA, et al. Differential effects of post-dilation after stent deployment in patients presenting with and without acute myocardial infarction. Am Heart J 2010;160:979-986.e1. https://doi.org/10.1016/j.ahj.2010.07.007
  21. Hong MK, Mintz GS, Lee CW, et al. Comparison of virtual histology to intravascular ultrasound of culprit coronary lesions in acute coronary syndrome and target coronary lesions in stable angina pectoris. Am J Cardiol 2007;100:953-9. https://doi.org/10.1016/j.amjcard.2007.04.034
  22. Hong YJ, Mintz GS, Kim SW, et al. Impact of plaque composition on cardiac troponin elevation after percutaneous coronary intervention: an ultrasound analysis. JACC Cardiovasc Imaging 2009;2:458-68. https://doi.org/10.1016/j.jcmg.2008.12.020
  23. Stone GW, Maehara A, Muller JE, et al. Plaque characterization to inform the prediction and prevention of periprocedural myocardial infarction during percutaneous coronary intervention: the CANARY Trial (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow). JACC Cardiovasc Interv 2015;8:927-36. https://doi.org/10.1016/j.jcin.2015.01.032
  24. Naidu SS, Krucoff MW, Rutledge DR, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv 2012;5:626-35.
  25. Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials. JACC Cardiovasc Interv 2011;4:1209-15. https://doi.org/10.1016/j.jcin.2011.07.016
  26. Kastrati A, Dibra A, Mehilli J, et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006;113:2293-300. https://doi.org/10.1161/CIRCULATIONAHA.105.601823
  27. Hong SJ, Kim MH, Ahn TH, et al. Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes. Heart 2006;92:1119-24. https://doi.org/10.1136/hrt.2005.075960

Cited by

  1. The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/6699812